Literature DB >> 29740849

Atorvastatin modulates drug transporters and ameliorates nicotine-induced testicular toxicity.

S Syam Das1, S S Nair1, M Indira1.   

Abstract

We studied the changes in mRNA expressions of influx and efflux transporters, blood-testis-barrier proteins (BTB) and key apoptotic genes in the testis of rats coadministered with nicotine and atorvastatin. Rats were divided into four groups: (i) control, (ii) atorvastatin (10 mg/kg b.wt), (iii) nicotine (0.6 mg/kg b.wt) and (iv) atorvastatin (10 mg/kg b.wt) + nicotine (0.6 mg/kg b.wt). Atorvastatin was given by oral intubation and nicotine by intraperitoneal injection. After 60 days of treatment, expressions of key apoptotic genes involved in both intrinsic and extrinsic pathways; solute carrier influx transporters SLCOB1, SLC22A1 and efflux transporter ABCB1 associated with transport of atorvastatin and nicotine, and proteins of BTB were assayed. Nicotine administration activated apoptosis and downregulated SLCOB1, which transport atorvastatin. Atorvastatin administration suppressed apoptotic pathway and downregulated SLC22A1, transporter of nicotine. Coadministration of atorvastatin with nicotine downregulated expressions of apoptotic genes. The combined administration of atorvastatin and nicotine reduced the influx of both atorvastatin and nicotine and enhanced the efflux of these drugs thereby altering the microenvironment of testis and improving testicular function. We conclude that atorvastatin-mediated alterations of BTB and drug transporters might have played a significant role in ameliorating nicotine-induced testicular toxicity.
© 2018 Blackwell Verlag GmbH.

Entities:  

Keywords:  ABCB1; SLC22A1; SLCOB1; atorvastatin; nicotine

Mesh:

Substances:

Year:  2018        PMID: 29740849     DOI: 10.1111/and.13029

Source DB:  PubMed          Journal:  Andrologia        ISSN: 0303-4569            Impact factor:   2.775


  2 in total

1.  Multimodal network diffusion predicts future disease-gene-chemical associations.

Authors:  Chih-Hsu Lin; Daniel M Konecki; Meng Liu; Stephen J Wilson; Huda Nassar; Angela D Wilkins; David F Gleich; Olivier Lichtarge
Journal:  Bioinformatics       Date:  2019-05-01       Impact factor: 6.937

2.  SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability.

Authors:  Pablo Zubiaur; Maria Dolores Benedicto; Gonzalo Villapalos-García; Marcos Navares-Gómez; Gina Mejía-Abril; Manuel Román; Samuel Martín-Vílchez; Dolores Ochoa; Francisco Abad-Santos
Journal:  J Pers Med       Date:  2021-03-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.